Literature DB >> 19936866

Flare-up of hand osteoarthritis caused by zoledronic acid infusion.

G R Werner de Castro1, F S Neves, S C de Magalhães Souza Fialho, I A Pereira, G Ribeiro, A F Zimmermann.   

Abstract

Zoledronic acid is effective for osteoporosis at a single annual intravenous dose. It usually causes few adverse effects; the most common are related to acute phase reactions. We reported the case of a 64-year-old woman who presented flare-up of hand osteoarthritis after zoledronic acid infusions. Despite the fact that arthralgia is a common side effect of intravenous bisphosphonates, development of inflammatory signs in osteoarthritic joints is a rare event. We hypothesized that this side effect is caused by a release of cytokines secondary to activation of gamma-delta T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19936866     DOI: 10.1007/s00198-009-1123-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  12 in total

1.  Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

Authors:  J E Dunford; K Thompson; F P Coxon; S P Luckman; F M Hahn; C D Poulter; F H Ebetino; M J Rogers
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

2.  Acute polyarthritis related to once-weekly alendronate in a woman with osteoporosis.

Authors:  Jean H Gerster
Journal:  J Rheumatol       Date:  2004-04       Impact factor: 4.666

3.  Bisphosphonate-associated arthritis.

Authors:  Alejandro Diaz-Borjon; Thorsten M Seyler; Natasha L Chen; S Sam Lim
Journal:  J Clin Rheumatol       Date:  2006-06       Impact factor: 3.517

4.  Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.

Authors:  E van Beek; E Pieterman; L Cohen; C Löwik; S Papapoulos
Journal:  Biochem Biophys Res Commun       Date:  1999-10-14       Impact factor: 3.575

5.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

6.  Alendronate-induced synovitis.

Authors:  David P Gwynne Jones; Ruth L Savage; John Highton
Journal:  J Rheumatol       Date:  2008-01-15       Impact factor: 4.666

7.  Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.

Authors:  Giordano Dicuonzo; Bruno Vincenzi; Daniele Santini; Giuseppe Avvisati; Laura Rocci; Fabrizio Battistoni; Michele Gavasci; Domenico Borzomati; Roberto Coppola; Giuseppe Tonini
Journal:  J Interferon Cytokine Res       Date:  2003-11       Impact factor: 2.607

Review 8.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors:  R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

9.  Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

Authors:  Keith Thompson; Michael J Rogers
Journal:  J Bone Miner Res       Date:  2003-12-16       Impact factor: 6.741

10.  The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins.

Authors:  R E Hewitt; A Lissina; A E Green; E S Slay; D A Price; A K Sewell
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

View more
  3 in total

1.  Severe polyarthritis secondary to zolendronic acid: a case report and literature review.

Authors:  Sarah Louise White; Alyssa Jacob; Celia Gregson; Ashok Bhalla
Journal:  Clin Cases Miner Bone Metab       Date:  2015 Jan-Apr

Review 2.  Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.

Authors:  Ronald C Hamdy
Journal:  Drug Des Devel Ther       Date:  2010-11-18       Impact factor: 4.162

3.  Future directions for the management of pain in osteoarthritis.

Authors:  Nidhi Sofat; Anasuya Kuttapitiya
Journal:  Int J Clin Rheumtol       Date:  2014-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.